Virtual ENCALS meeting 2021

This year, ENCALS (European Network to Cure ALS) will be organising their…

Words Lucie van Leeuwen.Published March 12, 2021
Virtual ENCALS meeting 2021

This year, ENCALS (European Network to Cure ALS) will be organising their annual meeting online. The meeting will take place on 12-14 May. Registration and abstract submission are now open.

More details of the programme will be announced once abstract submission has closed. Keep an eye on the ENCALS website to stay updated.

Registration and abstract submission

It is now possible to register for the Virtual ENCALS Meeting 2021 by accessing the following link: https://kuonicongress.eventsair.com/encals21/reg/Site/Register. For more information about registration fees, please visit the ENCALS website.

Abstracts can be submitted until 11:59 PM CET on Friday March 26th via: https://kuonicongress.eventsair.com/encals21/abstract-portal. Please note that you need to register for the event before you can submit an abstract. All abstracts will be reviewed by the ENCALS Programme Committee 2021. Applicants will receive a notification of acceptance as platform or poster presentation as soon as possible.

Sponsorship

Are you interested in sponsoring the Virtual ENCALS Meeting 2021? Please ask for the Sponsorship Prospectus 2021 via info@encals.eu.

 


Share

Related news

Meet the centre - Torino ALS Center (University of Torino)
Meet the centre - Torino ALS Center (University of Torino)
The TRICALS consortium currently consists of more than 40 centers across Europe. […]
Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Yesterday, the pharmaceutical company Amylyx announced that they are withdrawing the drug […]
Results of TUDCA-study: No effect of investigated compound
Results of TUDCA-study: No effect of investigated compound
The TUDCA-ALS consortium has announced the first findings of the TUDCA study, […]
Amylyx: no effect after analyzing phase 3 study
Amylyx: no effect after analyzing phase 3 study
The pharmaceutical company Amylyx announced the first results of the PHOENIX study. […]